Visão geral da empresa
A clinical-stage biotechnology entity, Cabaletta Bio, Inc. specializes in the discovery and development of engineered T cell therapies designed to treat patients suffering from autoimmune diseases. The company operates within the broader healthcare sector, specifically the biotechnology industry, which focuses on the application of biological processes to develop products for medical use. Its current market capitalization stands at $352.89M, while the company maintains an employee base of 154 individuals dedicated to its research and development initiatives. The valuation indicates a mid-sized public company with significant potential for expansion, yet the lack of reported annual revenue suggests the firm is still in a capital-intensive pre-revenue or early clinical development phase, typical for biotechnology firms where asset value is derived primarily from intellectual property and pipeline potential rather than current sales performance.
Saúde financeira
The financial statements report a net income of $-167,856,000 and an EBITDA of $-170,595,008, while revenue data is not available for the trailing twelve months. The substantial gap between the reported net income and EBITDA, both of which are deeply negative, reveals a cost structure dominated by high research and development expenditures and operating costs that have not yet been offset by commercial revenue generation. The company reports a free cash flow of $-81,283,128, indicating a significant cash burn rate that necessitates continuous capital raising to fund operations until product candidates reach market. Analysis of the margin profile shows a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, which collectively indicate that the company has not yet achieved profitability or positive cash conversion from its product sales. On the liability side, the company holds $133.60M in cash against $27.10M in debt, resulting in a debt-to-equity ratio of 24.18, which suggests a balance sheet that is currently leveraged but supported by a substantial cash reserve to service obligations. The current ratio is recorded at 2.77, a figure that indicates strong short-term liquidity relative to short-term liabilities, providing a buffer for operational continuity despite the negative earnings environment. Furthermore, the return on equity is -127.0% and the return on assets is -61.5%, metrics that reveal management is currently deploying capital to fund growth initiatives rather than generating immediate financial returns to shareholders.
Avaliação de valorização
Valuation metrics present a complex picture given the company's lack of profitability, with a trailing P/E ratio listed as N/A and a forward P/E of -2.26. The negative forward P/E implies that the market is pricing in expected future earnings based on current projections, though the divergence between the unavailable trailing P/E and the forward figure highlights the speculative nature of valuing a company with no historical earnings. The price-to-book ratio is 2.84, indicating that the market values the company at a significant premium over its net book value, likely reflecting the high value assigned to its intangible assets, such as intellectual property and clinical data. Alternative valuation metrics include a price-to-sales ratio of N/A and an EV/EBITDA of -1.44, suggesting that traditional multiple-based comparisons with profitable peers are not applicable at this stage of the company's lifecycle. Price action over the past year has seen significant volatility, with a 52-week high of $3.78 and a 52-week low of $1.01. Without a specific current price provided in the available facts to calculate the exact percentage deviation, the stock trades within this established range, exhibiting the high beta characteristic of biotech stocks. The beta value is 3.29, meaning the stock's price volatility is more than three times that of the broader market, reflecting the heightened risk premium investors demand for exposure to clinical-stage biotechnology ventures.
Growth & Income
Growth metrics for the company show revenue growth year-over-year as N/A and earnings growth year-over-year as N/A, reflecting the pre-commercial nature of the business. Since there is no revenue baseline, it is impossible to compare the growth rate of earnings against revenue in the traditional sense, as the company has not yet generated the sales volume required for such a comparison. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available cash flow is retained within the organization to fund ongoing research, development, and clinical trials rather than being distributed to shareholders. Consequently, the overall growth and income profile is characterized entirely by capital appreciation potential derived from clinical trial success and future commercialization, with no current income generation or dividend yield to support investors seeking regular cash flow.